JP2022540921A5 - - Google Patents
Info
- Publication number
- JP2022540921A5 JP2022540921A5 JP2022502559A JP2022502559A JP2022540921A5 JP 2022540921 A5 JP2022540921 A5 JP 2022540921A5 JP 2022502559 A JP2022502559 A JP 2022502559A JP 2022502559 A JP2022502559 A JP 2022502559A JP 2022540921 A5 JP2022540921 A5 JP 2022540921A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- subject
- compound
- treating
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962874474P | 2019-07-15 | 2019-07-15 | |
| US62/874,474 | 2019-07-15 | ||
| PCT/US2020/042162 WO2021011674A1 (en) | 2019-07-15 | 2020-07-15 | Methods useful in treating cancers harboring a kras or hras mutation or amplification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022540921A JP2022540921A (ja) | 2022-09-20 |
| JP2022540921A5 true JP2022540921A5 (cg-RX-API-DMAC7.html) | 2023-07-26 |
Family
ID=74211326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502559A Pending JP2022540921A (ja) | 2019-07-15 | 2020-07-15 | Krasまたはhras変異若しくは増幅を有するがんを処置する際に有用な方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220257599A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3999049A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022540921A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114364377A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020315388A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3147588A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021011674A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102679204B1 (ko) * | 2021-02-10 | 2024-06-27 | 한국생명공학연구원 | GPX4 저해제 및 Lp-PLA2 저해제를 포함하는 암 예방 또는 치료용 조성물 |
| WO2024077085A1 (en) * | 2022-10-07 | 2024-04-11 | Memorial Sloan-Kettering Cancer Center | Targeting phospholipase a2 (pla2) in cancer |
| US12314787B2 (en) | 2023-04-27 | 2025-05-27 | Hewlett Packard Enterprise Development Lp | Serving application programming interface calls directed to hierarchical data format files stored in fabric-attached memories |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150017671A1 (en) * | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
| AU2012240154A1 (en) * | 2011-04-06 | 2013-10-17 | The Scripps Research Institute | N1- and N2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods |
| CN102166364A (zh) * | 2011-04-14 | 2011-08-31 | 江南大学 | 用于治疗卵巢癌的钙离子非依赖性磷脂酶a2的抑制剂 |
| MX2016010213A (es) * | 2014-02-07 | 2017-04-13 | Auspex Pharmaceuticals Inc | Formulaciones farmaceuticas novedosas. |
| CN109715163B (zh) * | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
| US20190142835A1 (en) * | 2017-11-14 | 2019-05-16 | Oregon Health & Science University | Inhibition of autophagy using phospholipase a2 inhibitors |
-
2020
- 2020-07-15 WO PCT/US2020/042162 patent/WO2021011674A1/en not_active Ceased
- 2020-07-15 AU AU2020315388A patent/AU2020315388A1/en not_active Abandoned
- 2020-07-15 CN CN202080063214.7A patent/CN114364377A/zh active Pending
- 2020-07-15 US US17/626,370 patent/US20220257599A1/en not_active Abandoned
- 2020-07-15 EP EP20841099.3A patent/EP3999049A4/en not_active Withdrawn
- 2020-07-15 JP JP2022502559A patent/JP2022540921A/ja active Pending
- 2020-07-15 CA CA3147588A patent/CA3147588A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| Kalokasidis et al. | The effect of Q‐switched Nd: YAG 1064 nm/532 nm laser in the treatment of onychomycosis in vivo | |
| Parashar et al. | S‐adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: therapeutic and diagnostic clinical applications | |
| Zhang et al. | Development of tumor-evolution-targeted anticancer therapeutic nanomedicineEVT | |
| CY1118651T1 (el) | Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη | |
| JP2007530543A5 (cg-RX-API-DMAC7.html) | ||
| Liu et al. | Does chlorhexidine improve outcomes in non-surgical management of peri-implant mucositis or peri-implantitis?: a systematic review and meta-analysis | |
| Li et al. | Epithelial–mesenchymal transition in pulmonary fibrosis: molecular mechanisms and emerging therapeutic strategies | |
| Jebran et al. | Rapid healing of cutaneous leishmaniasis by high-frequency electrocauterization and hydrogel wound care with or without DAC N-055: a randomized controlled phase IIa trial in Kabul | |
| Pershing et al. | Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer | |
| Sápi et al. | Linear state-feedback control synthesis of tumor growth control in antiangiogenic therapy | |
| CN108079303A (zh) | 鞘氨醇激酶抑制剂在制备治疗肝纤维化药物中的应用 | |
| WO2022266302A8 (en) | Systems and methods for improved targeted therapy | |
| Bijlsma et al. | Are glucocorticoids DMARDs? | |
| Salari-Sharif et al. | Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review | |
| Zhu et al. | Theogallin protects myocardial ischemia-reperfusion injury by inhibiting the interleukin-17 signaling pathway | |
| Piretto et al. | How combination therapies shape drug resistance in heterogeneous tumoral populations | |
| Pastor et al. | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella | |
| Bokotas et al. | Wells syndrome: response to dapsone therapy | |
| CN109512822A (zh) | 一种治疗肝癌的联合药物组合物 | |
| Kotalik | Multiple daily fractions in radiotherapy | |
| Cheng et al. | Dose rectification of an imbalance between DPP 4 and GLP‐1 ameliorates chronic stress‐related vascular aging and atherosclerosis? | |
| CN109045013A (zh) | Nifuroxazide的医药新用途 | |
| CN116920098B (zh) | Depdc1在治疗肝癌中的应用 | |
| Soriano et al. | Treatment of cutaneous larva migrans with a single session of carbon dioxide laser: a study of ten cases in the Philippines |